(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/081927 A1

(51) International Patent Classification:
A61K 31/403 (2006.01) *C07D 401/04* (2006.01)
C07D 209/92 (2006.01) *C07D 403/04* (2006.01)

(21) International Application Number:
PCT/US2021/055104

(22) International Filing Date:
14 October 2021 (14.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/091,894 14 October 2020 (14.10.2020) US

(71) Applicant: **C4 THERAPEUTICS, INC.** [US/US]; 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US).

(72) Inventors: **NASVESCHUK, Christopher, G.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). **ANDERSON, Corey, Don**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). **HENDERSON, James, A.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). **GARZA, Victoria**; 10614 Burr Oak Drive, San Antonio, TX 78230 (US). **LIANG, Yanke**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). **MOUSTAKIM, Moses**; 240 Nw 25th Street, Apt. 822, Miami, FL 33127 (US). **O'SHEA, Morgan, Welzel**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US).

(74) Agent: **BELLOWS, Brent, R.**. et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY



FIG. 3

(57) Abstract: The invention provides tricyclic compounds that degrade neosubstrates for use in the treatment of disorders described herein, including, for example, abnormal cellular proliferation, neurodegenerative diseases, and autoimmune diseases.

WO 2022/081927 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*